Week in Review: Cellular Biomedicine of China to Reverse Merger in US
Cellular Biomedicine Group, a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group of the US; Guangzhou BeBetter Medicine signed a collaborative research agreement with Taiwan's PharmaEngine to develop oncology drugs; Tianjin KingYork Group and Innovata of Hong Kong formed an inhaled drug JV that will target asthma; and Sichuan Kelun Pharma paid $135 million to purchase a 12.3% stake in Lijun International Pharma. More details…. Stock Symbols: (OTCQB: EBIG) (TWO: 4162) (SHE: 002422) (HK: 2005) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here